• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Long-term enzyme-inducing antiseizure medication use associated with elevated hazard of incident cardiovascular disease

byYuchen DaiandMichael Pratte
October 5, 2021
in Cardiology, Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this cohort study, there was a dose-dependent association between enzyme-inducing antiseizure medication use and an elevated hazard of incident cardiovascular disease.

2. Short-term enzyme-inducing antiseizure medication therapy did not confer considerable risk, but caution should be used when taking these medications long-term, particularly in patients with late-onset epilepsy.

Evidence Rating Level: 2 (Good)

Study Rundown: Cardiovascular risk factors, such as hypertension, dyslipidemia, type 2 diabetes, and atrial fibrillation, are known to be more prevalent in individuals with adult-onset epilepsy, likely associated with epilepsy itself as well as sedentary behaviors, high rates of cigarette smoking, and lower socioeconomic status. Enzyme-inducing antiseizure medications (eiASMs) used for the treatment of epilepsy have also been hypothesized to contribute to long-term risks of cardiovascular disease. This cohort study sought to 1) compare the risk associated with eiASMs vs non-eiASMs, 2) evaluate the risks of eiASMS in incident cases of epilepsy, and 3) assess the risk of eiASM in patients with late-onset epilepsy diagnosed after 65 years who may be at greatest risk of the adverse effects of long-term eiASM therapy. The main endpoint was incident cardiovascular disease (ischemic heart disease or ischemic/hemorrhagic stroke). Among 31,479 patients, the hazard of incident cardiovascular disease was higher for those receiving 4 consecutive prescriptions for eiASMs compared with non-eiASMs. In addition, persistent use of eiASMs in patients showed that a higher defined daily dose was associated with an increase in incident cardiovascular disease compared with no eiASM throughout a maximum of 25 years follow-up. These findings demonstrated a dose-dependent association between eiASM use and an elevated hazard of incident cardiovascular disease. Short-term eiASM therapy did not confer considerable risk, but caution should be used when taking these medications long-term, particularly in patients with late-onset epilepsy. A limitation of this study was that the analyses of may have been subject to immortal time bias, where some patients may have developed and died of cardiovascular disease prior to epilepsy onset, resulting in a cohort that is misleadingly more resistant to cardiovascular disease due to survival advantage.

Click to read the study in JAMA Neurology

Relevant Reading: Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies

In-Depth [prospective cohort]: This cohort study included 50,888 adult patients with epilepsy (median [IQR] age, 32 [19-50] years; 16,584 [53%] female), of whom 31,479 (62%) were diagnosed between January 1990 to March 2019 and free of cardiovascular disease at baseline. Eligible patients 18 years or older from primary care and National Health Service centers in England received 4 consecutive eiASMs (carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, rufinamide, or topiramate) following a diagnosis of adult-onset epilepsy or repeated exposure in a weighted cumulative exposure model. For those receiving eiASMs, the hazard ratio for incident cardiovascular disease was 1.21 (95%CI, 1.06-1.39) using an adjusted propensity-matched survival analysis and weighted cumulative exposure model. In individuals with persistent exposure to eiASMs beyond 4 prescriptions, the hazard was associated with an increased risk of cardiovascular disease for those with a higher defined daily dose compared to no eiASMs throughout a maximum of 25 years follow-up (median HR [IQR], daily dose of 1: 1.54 [1.28-1.79]; daily dose of 2: 2.38 [1.52-3.56]). Lastly, the hazard was elevated but attenuated when restricting for incident cases or individuals with late-onset epilepsy diagnosed after 65 years.

RELATED REPORTS

Primary hyperparathyroidism associated with an increased risk of fractures and cardiovascular events

Prenatal exposure to antiseizure medication associated with increased risk of autism and intellectual disability

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascularcardiovascular eventscardiovascular mortalitycardiovascular riskseizures
Previous Post

Fixed-dose combination treatment with aspirin may reduce the risk of cardiovascular disease

Next Post

Men may be 2.5 times more likely to die from COVID-19 than women

RelatedReports

Forearm parathyroid reimplantation may be effective in preventing hypoparathyroidism
Chronic Disease

Primary hyperparathyroidism associated with an increased risk of fractures and cardiovascular events

June 13, 2022
Paternal factors associated with short interpregnancy interval
Neurology

Prenatal exposure to antiseizure medication associated with increased risk of autism and intellectual disability

June 3, 2022
FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Cardiology

Associations remain inconclusive between religiosity and spirituality on medication adherence in cardiovascular disease

May 16, 2022
Next Post

Men may be 2.5 times more likely to die from COVID-19 than women

Early language exposure is predictive of language skills and IQ in school-age children

Novel preemptive intervention effective in reducing autism spectrum disorder severity and rate of diagnosis

Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine

Use of menopausal hormone therapy and risk of dementia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.